Aandelen in “Testlaboratoria”

Aandeel Datum Koers Evolutie
vlag Genedrive Plc 21/04 0,950 GBX
-5,00% 		-5,00%
vlag Gerresheimer AG 21/04 22,040 EUR
+3,86% 		+3,86%

Nieuws over “Testlaboratoria”

08:30 · WENDEL: Wendel completes the acquisition of a controlling stake in Committed Advisors, adding expertise in secondary markets to its third-party asset management business · Persbericht

08:30 · WENDEL: Wendel completes the acquisition of a controlling stake in Committed Advisors, adding expertise in secondary markets to its third-party asset management business · Persbericht

8/04 · WENDEL: Shareholders’ Meeting set for May 21, 2026 · Persbericht

31/03 · WENDEL: Wendel Appoints Harper Mates  as CEO of Wendel North America  · Persbericht

30/03 · WENDEL: Availability of the 2025 Universal Registration Document  · Persbericht

25/03 · Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs · Persbericht

17/03 · PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas · Persbericht

27/02 · WENDEL: Share buybacks and liquidity agreement suspension · Persbericht

26/02 · WENDEL: 2025 Full-Year Results · Persbericht

19/02 · 10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference · Persbericht

17/02 · WENDEL: Wendel supports MTN’s offer to acquire IHS Towers pursuant to which it will receive full liquidity on its 19% stake, representing net proceeds of approximately $535m · Persbericht

12/02 · 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 · Persbericht

4/02 · PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology · Persbericht

4/02 · WENDEL: Agreement to sell Stahl, the global leader in specialty coatings for flexible materials, to Henkel · Persbericht

22/01 · 10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 · Persbericht

22/01 · Pilot Study Finds 30-Day Molecular Improvement in Prostate Health Following Intraprostatic Ozone Therapy, Tracked by the EpiSwitch® PSE Blood Test · Persbericht

Mijn selecties